公开(公告)号：US20240002532A1

公开(公告)日：2024-01-04

申请号：US18346130

申请日：2023-06-30

申请人： FATE THERAPEUTICS, INC. ,  ONO PHARMACEUTICAL CO., LTD.

发明人： Bahram VALAMEHR ,  Tom Tong LEE ,  Martin HOSKING ,  Susumu YAMAMOTO ,  Tatsuo MAEDA

IPC分类号： C07K16/32 ,  C07K14/705 ,  C07K14/725

CPC分类号： C07K16/32 ,  C07K14/70521 ,  C07K14/7051 ,  C07K2319/03 ,  C07K2319/02 ,  C07K2319/33

摘要： Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.

公开(公告)号：US20230405121A1

公开(公告)日：2023-12-21

申请号：US18250735

申请日：2021-11-04

申请人： Fate Therapeutics, Inc.

发明人： Bahram VALAMEHR ,  Martin HOSKING ,  Tom Tong LEE ,  John Charles GOULDING

IPC分类号： A61K39/00 ,  C12N5/0783 ,  C12N15/86 ,  C07K16/28 ,  C07K16/30 ,  C07K14/54 ,  C07K14/735 ,  A61K45/06 ,  A61P35/00 ,  C07K14/725

CPC分类号： A61K39/464411 ,  C12N5/0636 ,  C12N5/0646 ,  C12N15/86 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2851 ,  C07K14/5443 ,  C07K14/70535 ,  A61K45/06 ,  A61P35/00 ,  A61K39/4613 ,  A61K39/4611 ,  C07K16/283 ,  A61K39/4631 ,  A61K39/4635 ,  A61K39/4633 ,  A61K39/464466 ,  C07K14/7051 ,  C12N2506/45 ,  C12N2740/15043 ,  C07K2317/622 ,  A61K2239/27 ,  C07K2317/31 ,  A61K2039/572 ,  C07K2319/33

摘要： Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived effector cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

公开(公告)号：US20230357716A1

公开(公告)日：2023-11-09

申请号：US18345885

申请日：2023-06-30

申请人： FATE THERAPEUTICS, INC.

发明人： Bahram VALAMEHR ,  Tom Tong LEE ,  Martin HOSKING ,  Eigen PERALTA ,  Chia-Wei CHANG

IPC分类号： C12N5/078 ,  C07K14/725 ,  C07K16/30 ,  A61P35/00

CPC分类号： C12N5/0634 ,  C07K14/7051 ,  C07K16/3015 ,  A61P35/00 ,  C07K2317/565 ,  C07K2319/03 ,  C07K2319/02 ,  C07K2317/622

摘要： Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.